🟢 Immix Biopharma is trading 5.29% up today after Mizuho raised target to $26 from $15

Immix Biopharma is trading 5.29% up at $12.58 after Mizuho maintained an Outperform rating and raised its price target to $26 from $15.

• The analyst cited NXC-201’s potential second indication and expected NEXICART-2 Phase 2 data later in September.
• Broader risk appetite is supportive, with biotechnology up 2.55% and major U.S. indexes higher.